Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Raji, Rhoda ^a   Guzzo, Federica ^a   Carrara, Luisa ^a   Varughese, Joyce ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   Betti, Marta ^a   Todeschini, Paola ^a   Gasparrini, Sara ^a   Ratner, Elena ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter ^a   Rutherford, Thomas J ^a   Buza, Natalia ^a   Pecorelli, Sergio ^b   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

carcinosarcoma; hRS7; immunotherapy; natural killer cell; Trop 2

Indexed keywords

CELL ANTIBODY; CELL SURFACE MARKER; CHROMIUM; HRS7 ANTIBODY; TROPHOBLASTIC CELL SURFACE MARKER 2; TROPHOBLASTIC CELL SURFACE MARKER 2 ANTIBODY; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; COMPLEMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERUS CARCINOMA; AGED; CARCINOSARCOMA; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; OVARY TUMOR; TUMOR CELL LINE; UTERUS; UTERUS CANCER;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CARCINOSARCOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; OVARIAN NEOPLASMS; TRANSCRIPTION, GENETIC; UTERINE NEOPLASMS; UTERUS;

EID: 80755159321     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-106     Document Type: Article

References (18)

1. Molecular genetic aberrations of ovarian and uterine carcinosarcomas - a CGH and FISH study. Schipf A, Mayr D, Kirchner T, Diebold J, Virchows Arch 2008 452 3 259 268 10.1007/s00428-007-0557-6 18193277
2. Carcinosarcoma of the ovary a review. Cantrell LA, Van Le L, Obstet Gynecol Surv 2009 64 10 673 80 quiz 697 10.1097/OGX.0b013e3181b8aff3 19772676
3. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 5 277 300 10.3322/caac.20073 20610543
4. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr, Gynecol Oncol 2006 100 3 561 564 10.1016/j.ygyno.2005.09.017 16271748 (Pubitemid 43246873)
5. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A, Cochrane Database Syst Rev 2011 1 1 D006812 21249682
6. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT, Int J Gynecol Cancer 2010 20 5 888 894 10.1111/IGC. 0b013e3181dc8292 20606539
7. Human Trop-2 is a tumor-associated calcium signal transducer. Ripani E, Sacchetti A, Corda D, Alberti S, Int J Cancer 1998 76 5 671 676 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 9610724 (Pubitemid 28243939)
8. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Cubas R, Zhang S, Li M, Chen C, Yao Q, Mol Cancer 2010 9 253 10.1186/1476-4598-9-253 20858281
9. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD, Eur J Cancer 2010 46 5 944 953 10.1016/j.ejca.2009.12.019 20060709
10. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD, Cancer 2011 117 14 3163 3172 10.1002/cncr.25891 21246534
11. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM, Breast Cancer Res Treat 2004 84 2 173 182 10.1023/B:BREA.0000018417.02580.ef 14999147 (Pubitemid 38393367)
12. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM, Clin Cancer Res 2011 17 10 3157 3169 10.1158/1078-0432.CCR-10-2939 21372224
13. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Chang CH, Gupta P, Michel R, Loo M, Wang Y, Cardillo TM, Goldenberg DM, Mol Cancer Ther 2010 9 8 2276 2286 10.1158/1535-7163.MCT-10-0338 20663928
14. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM, Int J Cancer 1993 55 6 938 946 10.1002/ijc.2910550611 8253531 (Pubitemid 24005338)
15. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM, Clin Cancer Res 1999 5 10 Suppl 3079s 3087s 10541347 (Pubitemid 29493899)
16. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Cubas R, Li M, Chen C, Yao Q, Biochim Biophys Acta 2009 1796 2 309 314 19683559
17. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Wang J, Day R, Dong Y, Weintraub SJ, Michel L, Mol Cancer Ther 2008 7 2 280 285 10.1158/1535-7163.MCT-07-2003 18281513 (Pubitemid 351302522)
18. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Guerra E, Trerotola M, Dell'Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M, Alberti S, Cancer Res 2008 68 19 8113 8121 10.1158/0008-5472.CAN-07-6135 18829570